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Abstract
Background: Data on asthma burden in pediatric patients are limited; this
real‐world study investigated exacerbation frequency and health care re-
source utilization (HCRU) in pediatric asthma patients from the US and
England.
Methods: Data from pediatric patients (aged 6‐17 years) in the Optum
claims database (US) or Clinical Practice Research Datalink with linkage to
Hospital Episode Statistics (England) were analyzed. Patients were cate-
gorized into four hierarchical groups: treated asthma (patients with ≥1
baseline asthma medication), severe asthma (plus Global Initiative for
Asthma Step 4/5), severe refractory asthma ([SRA] plus ≥2 baseline severe
asthma exacerbations), and eosinophilic SRA (SRA plus blood eosinophil
count ≥150 cells/µL). Exacerbation frequency and HCRU during the
12 months postindex were described.
Results: Of 151 549 treated asthma patients in the US, 18 086 had severe
asthma, 2099 SRA, and 109 eosinophilic SRA. There were 32 893 treated
asthma patients in England, of whom 2711 had severe asthma, 265
SRA, and 8 eosinophilic SRA. In the 12 months postindex, ≥1 exacerbation
occurred in 12.4% and 10.8% of patients with severe asthma, and 32.6%
and 42.6% with SRA in the US and England, respectively. The proportions
of patients with ≥1 asthma hospitalization in the 30 days after the first
asthma exacerbation were 2.7% and 4.4% (treated), 3.5% and 8.2% (severe
asthma), and 6.0% and 16.8% (SRA) in the US and England, respectively.
Conclusion: This study provides insights into current asthma management
practices in the US and England and indicates that some patients with severe
disease have an unmet need for effective management.
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1 | INTRODUCTION
Asthma in children and adolescents poses a substantial
burden not only on global health care systems but also on
the lives of the patients and their families.1,2 Around 5%
of pediatric patients with asthma have severe disease,3,4
which is characterized by uncontrolled symptoms despite
treatment with high‐dose inhaled corticosteroids (ICS)
and/or oral corticosteroids (OCS).5,6 Severe asthma ac-
counts for over 50% of asthma‐related costs and is asso-
ciated with more frequent exacerbations (or asthma
attacks) than nonsevere asthma.7‐10 Furthermore, severe
asthma or uncontrolled asthma is associated with in-
creased health care resource utilization (HCRU), with
patients more likely to require OCS treatment and
emergency department (ED) visits or hospitalization.11‐15
The prevalence of asthma in both children and ado-
lescents is increasing globally.1 However, reported pre-
valence estimates vary greatly between countries,16‐19
likely owing to differences in country socioeconomic
statuses, environmental factors, and patient access to
treatment. The use of different disease definitions also
makes it challenging to compare data between coun-
tries.20 Understanding the real‐world burden of disease
and HCRU in pediatric patients with asthma would likely
help to ensure resources to optimize disease management
are directed to those patients with unmet needs. Fur-
thermore, the existing limited information on the global
burden of pediatric asthma is difficult to compare across
regions given the differences in health care settings and
treatment conventions between countries, as well as the
differing methodologies used to define study populations.
With this in mind, this study characterized patients aged
6 to 17 years with asthma in terms of exacerbation
frequency, treatments prescribed and HCRU, using
real‐world data from the US and England. Similar data
analysis methodology was used across both datasets and
data from the same time period were analyzed.
2 | METHODS
2.1 | Study design
We report results from two retrospective cohort studies
(GlaxoSmithKline IDs: 208944; PRJ3070) using data from
two databases: the Optum claims database (US popula-
tion) and the Clinical Practice Research Datalink (CPRD)
General Practice Online Data database with linkage to
Hospital Episode Statistics data (England population). In
each study, the population comprised pediatric patients
who had ≥1 asthma diagnostic code recorded between 1
January 2011 and 31 December 2015. The index date was
defined as the date of the most recent asthma record
when the patient met all other inclusion and exclusion
criteria. The England study was approved by the In-
dependent Scientific Advisory Committee of CPRD. The
US study used fully deidentified retrospective claims
data, and as such, was not classified as research involving
human participants as defined by 45 CFR 46.102(f)(2).
Therefore, institutional review board approval and in-
formed consent were not required.
2.2 | Study population
In addition to ≥1 asthma diagnostic code (Table S1)
during the cohort definition period, eligible patients were
6 to 17 years of age at index, had been prescribed ≥1
asthma medication during the 3 months before index,
and had been continuously enrolled/registered in the
respective databases during the 12‐month period before
and including the index date (baseline period) and the
12 months after the index date (follow‐up period). Any
patient with a diagnosis of cystic fibrosis (both popula-
tions) or with a code denoting “asthma resolved” during
the 12‐month baseline or follow‐up periods (England
population only) were excluded. Patients in the CPRD
database were also required to be eligible for the Hospital
Episode Statistics linkage.
Patients were classified into asthma severity cate-
gories based on the Global Initiative for Asthma (GINA)
guidelines (GINA Steps 1‐5).7 Four hierarchical asthma
groups were used, reflecting increasing asthma severity:
(a) the treated asthma group (patients with ≥1 baseline
asthma medication), (b) the severe asthma group (pre-
vious group restricted to patients meeting the GINA Step
4/5 criteria), (c) the severe refractory asthma group
(previous group restricted to ≥2 baseline severe asthma
exacerbations), and (d) the severe refractory eosinophilic
asthma group (previous group restricted to baseline blood
eosinophil count ≥150 cells/µL).
2.3 | Outcomes and assessments
Patient demographics, exacerbations, clinical character-
istics, and GINA step classification during the baseline
period were recorded. If available, blood eosinophil
counts nearest to the index date were recorded within a
period of 6 months preindex to 6 months postindex.
Outcomes recorded in the follow‐up period included the
frequency of severe asthma exacerbations, and all‐cause
and asthma‐specific HCRU (office visits, outpatient visits
[US population only], ED visits, hospitalizations, pre-
scription medications dispensed) recorded during the
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30 days following the first severe asthma exacerbation.
Among patients who had ≥1 asthma‐related hospitali-
zation discharge during the follow‐up period, the fre-
quency of hospital readmission within 30 and 90 days
following the first observed hospital discharge during the
follow‐up period was determined. The number of
asthma‐related medications prescribed within 30 days
following the first‐hospital discharge during the follow‐
up period was also determined.
Severe asthma exacerbations were measured as any
type of exacerbation or separately as exacerbations re-
sulting in hospitalization, ED visit, or a short course of
high‐dose OCS. Exacerbations occurring within 7 days of
a previous event were considered to be part of the same
exacerbation.
2.4 | Statistical analysis
Descriptive statistics were performed separately for each
of the four asthma groups for each country; no com-
parative analyses were conducted.
3 | RESULTS
3.1 | Patient population
Overall, there were 151 549 and 32 893 pediatric patients
(6‐17 years of age) included in the treated asthma group,
18 086 (11.9%) and 2711 (8.2%) patients included in the
severe asthma group, 2099 (1.4%) and 265 (0.8%) patients
included in the severe refractory asthma group, and 109
(0.1%) and 8 (0.02%) patients included in the severe
refractory eosinophilic asthma group in the US and
England, respectively (Figure 1). The severe refractory
eosinophilic asthma group from England was not ana-
lyzed further owing to very small patient numbers.
Demographic and clinical characteristics by the group are
shown in Table 1. The median (interquartile range) age at
index across all groups ranged from 10.0 (8.0‐14.0) to 12.0
(9.0‐15.0) years in the US and 12.0 (9.0‐15.0) to 14.0
(11.0‐16.0) years in England. Across all groups, the pro-
portion of patients experiencing ≥1 exacerbation during
the baseline period ranged from 24.5% to 100.0% in the
US and from 12.4% to 100.0% in England.
3.2 | Exacerbations during follow‐up
In both the US and England, the proportion of patients
experiencing ≥1 exacerbation during the follow‐up peri-
od was lowest in the treated asthma group for any ex-
acerbation type and increased with asthma severity
(Figure 2). For example, in the treated asthma group,
6.3% of the US population and 3.9% of the England
population experienced ≥1 exacerbation during follow‐up;
in the severe refractory asthma group, this increased to
32.6% and 42.6%, respectively (Figure 2). In the treated
asthma group, the proportion of patients experiencing ≥1
exacerbation resulting in hospitalization was 0.3% in the
US population and 1.0% in the England population, in-
creasing to 3.5% and 24.5%, respectively, in the severe
refractory asthma group (Figure 2). In both populations,
OCS‐defined exacerbations were the most common
exacerbation type. Furthermore, the number of
FIGURE 1 Overview of the hierarchical
asthma severity groups in this study. The
total numbers of patients who had an asthma
diagnosis within the cohort definition period
and were of any age in the US and England
populations were 2275, 845, and 517 369,
respectively. GINA, Global Initiative for
Asthma
238 | GOKHALE ET AL.
T
A
B
L
E
1
D
em
og
ra
ph
ic
an
d
cl
in
ic
al
ch
ar
ac
te
ri
st
ic
s
U
S
p
op
u
la
ti
on
E
n
gl
an
d
p
op
u
la
ti
on
a
T
re
at
ed
Se
ve
re
Se
ve
re
re
fr
ac
to
ry
Se
ve
re
re
fr
ac
to
ry
eo
si
n
op
h
il
ic
T
re
at
ed
Se
ve
re
Se
ve
re
re
fr
ac
to
ry
T
ot
al
,
n
15
1
54
9
18
08
6
20
99
10
9
32
89
3
27
11
26
5
Se
x,
m
al
e,
n
(%
)
87
23
0
(5
7.
6)
10
77
0
(5
9.
5)
12
62
(6
0.
1)
68
(6
2.
4)
18
90
9
(5
7.
5)
14
54
(5
3.
6)
13
0
(4
9.
1)
A
ge
at
in
de
x
da
te
,
y,
m
ed
ia
n
(I
Q
R
)
11
.0
(8
.0
,
14
.0
)
12
.0
(9
.0
,
15
.0
)
10
.0
(8
.0
,
14
.0
)
11
.0
(9
.0
,
16
.0
)
12
.0
(9
.0
,1
5.
0)
14
.0
(1
1.
0,
16
.0
)
13
.0
(1
0.
0,
16
.0
)
A
ge
gr
ou
p,
y,
n
(%
)
6‐
11
77
72
1
(5
1.
3)
89
90
(4
9.
7)
12
61
(6
0.
1)
56
(5
1.
4)
14
28
2
(4
3.
4)
81
9
(3
0.
2)
10
4
(3
9.
2)
12
‐1
7
73
82
8
(4
8.
7)
90
96
(5
0.
3)
83
8
(3
9.
9)
53
(4
8.
6)
18
61
1
(5
6.
6)
18
92
(6
9.
8)
16
1
(6
0.
8)
G
IN
A
St
ep
,
n
(%
)
N
on
e
63
6
(0
.4
)
N
A
N
A
N
A
19
9
(0
.6
)
N
A
N
A
1
68
26
8
(4
5.
0)
N
A
N
A
N
A
82
56
(2
5.
1)
N
A
N
A
2
34
40
4
(2
2.
7)
N
A
N
A
N
A
69
66
(2
1.
2)
N
A
N
A
3
30
15
5
(1
9.
9)
N
A
N
A
N
A
14
76
1
(4
4.
9)
N
A
N
A
4
17
90
5
(1
1.
8)
17
90
5
(9
9.
0)
20
67
(9
8.
5)
10
6
(9
7.
2)
27
04
(8
.2
)
27
04
(9
9.
7)
26
2
(9
8.
9)
5
18
1
(0
.1
)
18
1
(1
.0
)
32
(1
.5
)
3
(2
.8
)
7
(<
0.
1)
7
(0
.3
)
3
(1
.1
)
Se
ve
re
as
th
m
a
ex
ac
er
ba
ti
on
s
pe
r
pa
ti
en
t
du
ri
n
g
th
e
ba
se
li
n
e
pe
ri
od
,
by
ty
pe
,b
m
ed
ia
n
(r
an
ge
)
A
ll
ty
pe
s
0
(0
,
31
)
0
(0
,
21
)
2
(2
,
21
)
2
(2
,
7)
0
(0
,
15
)
0
(0
,
15
)
2
(2
,
15
)
O
C
S‐
de
fi
n
ed
ex
ac
er
ba
ti
on
s
0
(0
,
7)
0
(0
,
7)
2
(0
,
7)
2
(0
,
6)
0
(0
,
13
)
0
(0
,
13
)
2
(0
,
13
)
E
xa
ce
rb
at
io
n
s
re
su
lt
in
g
in
E
D
vi
si
t
0
(0
,
31
)
0
(0
,
21
)
0
(0
,
21
)
0
(0
,
5)
0
(0
,
12
)
0
(0
,
12
)
0
(0
,
12
)
E
xa
ce
rb
at
io
n
s
re
su
lt
in
g
in
h
os
pi
ta
li
za
ti
on
0
(0
,
4)
0
(0
,
4)
0
(0
,
4)
0
(0
,
4)
0
(0
,
17
)
0
(0
,
17
)
0
(0
,
17
)
N
u
m
be
r
of
se
ve
re
as
th
m
a
ex
ac
er
ba
ti
on
s
ex
pe
ri
en
ce
d
du
ri
n
g
th
e
ba
se
li
n
e
pe
ri
od
,
al
l
ty
pe
s,
n
(%
)
0
11
4
47
7
(7
5.
5)
11
58
0
(6
4.
0)
N
A
N
A
28
81
0
(8
7.
6)
19
41
(7
1.
8)
N
A
1
29
56
5
(1
9.
5)
44
07
(2
4.
4)
N
A
N
A
32
63
(9
.9
)
49
9
(1
8.
4)
N
A
2
56
60
(3
.7
)
14
15
(7
.8
)
14
15
(6
7.
4)
71
(6
5.
1)
58
3
(1
.8
)
14
8
(5
.5
)
14
8
(5
5.
8)
3
13
57
(0
.9
)
46
1
(2
.5
)
46
1
(2
2.
0)
20
(1
8.
3)
15
3
(0
.5
)
66
(2
.4
)
66
(2
4.
9)
≥
4
49
0
(0
.3
)
22
3
(1
.2
)
22
3
(1
0.
6)
18
(1
6.
5)
84
(0
.3
)
51
(1
.9
)
51
(1
9.
2)
N
u
m
be
r
of
se
ve
re
O
C
S‐
de
fi
n
ed
ex
ac
er
ba
ti
on
sc
ex
pe
ri
en
ce
d
du
ri
n
g
th
e
ba
se
li
n
e
pe
ri
od
,
n
(%
)
0
11
7
67
3
(7
7.
6)
12
04
5
(6
6.
6)
67
(3
.2
)
2
(1
.8
)
29
52
9
(8
9.
8)
20
72
(7
6.
4)
26
(9
.8
)
1
27
57
7
(1
8.
2)
42
27
(2
3.
4)
21
8
(1
0.
4)
12
(1
1.
0)
26
98
(8
.2
)
42
8
(1
5.
8)
56
(2
1.
1)
≥
2
62
99
(4
.2
)
18
14
(1
0.
0)
18
14
(8
6.
4)
95
(8
7.
2)
66
6
(2
.0
)
21
1
(7
.8
)
18
3
(6
9.
1)
(C
on
ti
n
u
es
)
GOKHALE ET AL. | 239
T
A
B
L
E
1
(C
on
ti
n
u
ed
)
U
S
p
op
u
la
ti
on
E
n
gl
an
d
p
op
u
la
ti
on
a
T
re
at
ed
Se
ve
re
Se
ve
re
re
fr
ac
to
ry
Se
ve
re
re
fr
ac
to
ry
eo
si
n
op
h
il
ic
T
re
at
ed
Se
ve
re
Se
ve
re
re
fr
ac
to
ry
N
u
m
be
r
of
se
ve
re
ex
ac
er
ba
ti
on
s
re
su
lt
in
g
in
E
D
vi
si
t
ex
pe
ri
en
ce
d
du
ri
n
g
th
e
ba
se
li
n
e
pe
ri
od
,
n
(%
)
0
14
4
94
0
(9
5.
6)
16
89
7
(9
3.
4)
14
74
(7
0.
2)
74
(6
7.
9)
32
26
1
(9
8.
1)
25
63
(9
4.
5)
18
4
(6
9.
4)
1
58
09
(3
.8
)
97
1
(5
.4
)
40
7
(1
9.
4)
21
(1
9.
3)
52
9
(1
.6
)
10
9
(4
.0
)
42
(1
5.
8)
≥
2
80
0
(0
.5
)
21
8
(1
.2
)
21
8
(1
0.
4)
14
(1
2.
8)
10
3
(0
.3
)
39
(1
.4
)
39
(1
4.
7)
N
u
m
be
r
of
se
ve
re
ex
ac
er
ba
ti
on
s
re
su
lt
in
g
in
h
os
pi
ta
li
za
ti
on
ex
pe
ri
en
ce
d
du
ri
n
g
th
e
ba
se
li
n
e
pe
ri
od
,
n
(%
)
0
14
9
74
9
(9
8.
8)
17
59
4
(9
7.
3)
18
13
(8
6.
4)
95
(8
7.
2)
32
20
4
(9
7.
9)
25
23
(9
3.
1)
14
7
(5
5.
5)
1
16
57
(1
.1
)
43
8
(2
.4
)
23
2
(1
1.
1)
7
(6
.4
)
55
2
(1
.7
)
12
6
(4
.6
)
60
(2
2.
6)
≥
2
14
3
(0
.1
)
54
(0
.3
)
54
(2
.6
)
7
(6
.4
)
13
7
(0
.4
)
62
(2
.3
)
58
(2
1.
9)
P
at
ie
n
ts
w
it
h
bl
oo
d
eo
si
n
op
h
il
m
ea
su
re
m
en
ts
,
n
(%
)
10
17
6
(6
.7
)
14
03
(7
.8
)
17
7
(8
.4
)
10
9
(1
00
)
28
9
(0
.9
)
28
(1
.0
)
8
(3
.0
)
E
os
in
op
h
il
co
u
n
ts
,
ce
lls
/µ
L
,
m
ed
ia
n
(I
Q
R
)d
20
0
(1
00
‐4
00
)
20
0
(1
00
‐3
94
)
20
0
(1
00
‐4
47
)
40
0
(2
03
‐6
00
)
33
8
(1
63
‐5
60
)
38
0
(1
70
‐7
90
)
…
E
os
in
op
h
il
ca
te
go
ry
,
n
(%
)d
<
15
0
ce
lls
/µ
L
38
85
(2
.6
)
57
3
(3
.2
)
68
(3
.2
)
N
A
70
(0
.2
)
6
(0
.2
)
…
≥
15
0
to
<
30
0
ce
lls
/µ
L
23
46
(1
.5
)
31
1
(1
.7
)
32
(1
.5
)
32
(2
9.
4)
59
(0
.2
)
5
(0
.2
)
…
≥
30
0
ce
lls
/µ
L
39
45
(2
.6
)
51
9
(2
.9
)
77
(3
.7
)
77
(7
0.
6)
16
0
(0
.5
)
17
(0
.6
)
…
N
ot
e:
U
S‐
tr
ea
te
d
as
th
m
a
gr
ou
p:
n
=
15
1
54
9,
U
S
se
ve
re
as
th
m
a
gr
ou
p:
n
=
18
08
6,
U
S
se
ve
re
re
fr
ac
to
ry
as
th
m
a
gr
ou
p:
n
=
20
99
,U
S
se
ve
re
re
fr
ac
to
ry
eo
si
n
op
h
il
ic
as
th
m
a
gr
ou
p:
n
=
10
9,
E
n
gl
an
d‐
tr
ea
te
d
as
th
m
a
gr
ou
p:
n
=
32
89
3,
E
n
gl
an
d
se
ve
re
as
th
m
a
gr
ou
p:
n
=
27
11
,E
n
gl
an
d
se
ve
re
re
fr
ac
to
ry
as
th
m
a
gr
ou
p:
n
=
26
5.
In
th
e
E
n
gl
an
d
po
pu
la
ti
on
da
ta
fo
r
th
e
se
ve
re
re
fr
ac
to
ry
eo
si
n
op
h
il
ic
as
th
m
a
gr
ou
p
ar
e
n
ot
re
po
rt
ed
ow
in
g
to
th
e
sm
al
l
sa
m
pl
e
si
ze
.
A
bb
re
vi
at
io
n
s:
E
D
,
em
er
ge
n
cy
de
pa
rt
m
en
t;
G
IN
A
,
G
lo
ba
l
In
it
ia
ti
ve
fo
r
A
st
h
m
a;
IQ
R
,
in
te
rq
u
ar
ti
le
ra
n
ge
;
N
A
,
n
ot
ap
pl
ic
ab
le
;
O
C
S,
or
al
co
rt
ic
os
te
ro
id
.
a D
at
a
fo
r
th
e
se
ve
re
re
fr
ac
to
ry
eo
si
n
op
h
il
ic
as
th
m
a
gr
ou
p
(n
=
8)
ar
e
n
ot
re
po
rt
ed
ow
in
g
to
th
e
sm
al
l
sa
m
pl
e
si
ze
.
b
T
h
e
m
ax
im
u
m
n
u
m
be
r
of
ex
ac
er
ba
ti
on
s
w
it
h
in
th
e
“a
ll
‐ty
pe
”
ca
te
go
ry
m
ay
be
lo
w
er
th
an
th
e
m
ax
im
u
m
es
ti
m
at
ed
w
h
en
co
n
si
de
ri
n
g
ea
ch
ty
pe
of
ex
ac
er
ba
ti
on
se
pa
ra
te
ly
.T
h
is
is
du
e
to
th
e
re
qu
ir
em
en
tf
or
a
7
d
ga
p
be
tw
ee
n
ea
ch
u
n
iq
u
e
ex
ac
er
ba
ti
on
.
c D
ef
in
ed
as
O
C
S
pr
es
cr
ip
ti
on
(E
n
gl
an
d
po
pu
la
ti
on
)
or
an
y
O
C
S
pr
es
cr
ip
ti
on
eq
u
iv
al
en
t
to
pr
ed
n
is
on
e
20
m
g/
d
fo
r
3
to
28
d
(U
S
po
pu
la
ti
on
)
re
co
rd
ed
w
it
h
in
1
w
k
be
fo
re
or
1
w
k
fo
llo
w
in
g
an
as
th
m
a
di
ag
n
os
is
co
de
.
d
A
n
al
ys
es
of
eo
si
n
op
h
il
co
u
n
ts
w
er
e
n
ot
pe
rf
or
m
ed
fo
r
th
e
se
ve
re
re
fr
ac
to
ry
as
th
m
a
gr
ou
p
in
E
n
gl
an
d
ow
in
g
to
th
e
sm
al
l
sa
m
pl
e
si
ze
(n
=
8)
.
240 | GOKHALE ET AL.
exacerbations experienced during follow‐up increased
with increasing GINA step (Table S2) and with increasing
exacerbation frequency in the baseline period (Table S3).
3.3 | HCRU in the 30 days following the
first severe asthma exacerbation
In the US, all‐cause and asthma‐related HCRU were
lower in the treated asthma group and increased with
disease severity (Figure 3A). For example, 2.7% and 5.2%
of patients with treated asthma, 3.5% and 8.6% with se-
vere asthma, and 6.0% and 13.6% with severe refractory
asthma had ≥1 asthma‐specific inpatient or outpatient
hospitalization visit, respectively. Similarly, the propor-
tion of patients with ≥1 asthma‐specific ED visit ranged
from 2.1% among patients with treated asthma to 4.5% in
patients with severe refractory asthma (Figure 3A).
Similar trends were seen in the population from
England (Figure 3B). For example, 4.4% of patients with
treated asthma, 8.2% with severe asthma, and 16.8% with
severe refractory asthma had ≥1 asthma‐specific hospi-
talization visit. In addition, the proportion of patients
with ≥1 asthma‐specific ED visit ranged from 2.4% in the
treated asthma group to 7.1% in the severe refractory
asthma group (Figure 3B). There was also a trend toward
higher all‐cause and asthma‐related HCRU with an
increasing number of exacerbations in the baseline
period (Table S4).
3.4 | Hospital readmissions within 30 or
90 days following the first severe asthma
exacerbation
In England, hospital readmissions within 30 or 90 days
following the first severe asthma exacerbation discharge
were lowest in the treated asthma group (8.7% and 20.8%,
respectively) and increased with disease severity to 22.5%
and 42.3% in the severe refractory asthma group
(Figure 4). In the US, no such pattern was observed, and
the proportion of patients with readmissions ranged from
24.3% to 29.9% for readmissions within 30 days and 28.8%
to 33.0% for those within 90 days (Figure 4).
3.5 | Asthma treatments within 30 days
following the first hospital discharge after
an asthma exacerbation
Overall, in both the US and England, short‐acting beta‐
agonists (SABAs) were the most commonly prescribed
asthma medication within 30 days following the
first hospital discharge after an asthma exacerbation in
FIGURE 2 Exacerbations during the follow‐up period. US‐treated asthma group: n = 151 549, US severe asthma group: n = 18 086,
US severe refractory asthma group: n = 2099, US severe refractory eosinophilic asthma group: n = 109, England‐treated asthma group:
n = 32 893, England severe asthma group: n = 2711, England severe refractory asthma group: n = 265. Asthma exacerbations were defined as
any exacerbation with asthma in the primary position for exacerbations that resulted in hospitalization or an emergency department (ED)
visit. Oral corticosteroid (OCS)‐defined exacerbations were defined as OCS prescription (England population) or any OCS prescription
equivalent to prednisone 20mg/d for 3 to 28 days (US population) recorded within 1 week before or 1 week following an asthma diagnosis
code. In the England population, data for the severe refractory eosinophilic asthma group are not reported owing to the small sample size
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(A)
(B)
FIGURE 3 Health care resource
utilization (HCRU) in the 30 days
following the first severe asthma
exacerbation in (A) the US and (B)
England. US‐treated asthma group:
n = 151 549, US severe asthma group:
n = 18 086, US severe refractory asthma
group: n = 2099, US severe refractory
eosinophilic asthma group: n = 109,
England‐treated asthma group: n = 32 893,
England severe asthma group: n = 2711,
England severe refractory asthma group:
n = 265. In the England population, data
for the severe refractory eosinophilic
asthma group are not reported owing to
the small sample size. ED, emergency
department
FIGURE 4 Readmissions following the first‐hospital discharge. US‐treated asthma group: n = 151 549, US severe asthma group:
n = 18 086, US severe refractory asthma group: n = 2099, US severe refractory eosinophilic asthma group: n = 109, England‐treated asthma
group: n = 32 893, England severe asthma group: n = 2711, England severe refractory asthma group: n = 265. In the England population,
data for the severe refractory eosinophilic asthma group are not reported owing to the small sample size
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all groups (Figure S1). The proportion of patients
receiving SABA prescriptions was lower in the US (50.8%‐
61.1% across severity groups) than in England (84.2%‐
89.1%). In the US, leukotriene receptor antagonists
(LTRAs) and OCS were prescribed in 40.7% to 60.0% and
41.7% to 60.0% of patients, respectively, within 30 days of
first hospital discharge, followed by ICS (0.0%‐33.3%) and
ICS‐long‐acting beta‐agonist (LABA) (20.0%‐35.2%)
(Figure S1A). In England, ICS‐LABA was prescribed in
39.1% to 61.8% of patients within 30 days of first‐hospital
discharge, followed by OCS (23.3%‐32.7%), ICS (9.1%‐
29.8%), and LABA (3.3%‐6.2%) (Figure S1B).
4 | DISCUSSION
In this retrospective, real‐world study of data from pe-
diatric patients from two large databases from England
and the US, exacerbation frequency and HCRU tended to
increase with asthma severity, indicating that disease
burden increases with disease severity. The overall trend
for a higher burden of exacerbations and HCRU in pe-
diatric patients with more severe asthma is consistent
with trends reported in adults.7,9‐12 Moreover, our find-
ings are consistent with those from another study con-
ducted in adolescents (aged≥ 12 years) and adult patients
with asthma,8 thus highlighting the need for improved
disease management in both pediatric and adult patients
with severe disease. As expected, across all groups,
asthma exacerbations during the follow‐up period were
more frequent if patients had more exacerbations in the
baseline period. Previous studies have also reported an
association between asthma exacerbation history and
future exacerbation risk.8,21‐23
While our results highlight the proportions of patients
in the different asthma groups that have unmet treatment
needs, our findings also indicate some positive observa-
tions with regard to current asthma management prac-
tices. For example, of the patients with severe refractory
asthma who were required by definition to have ≥2
baseline exacerbations, only around 32% of patients in
the US and 42% of patients in England had ≥1 exacer-
bation (any type) during the follow‐up period. These re-
sults support the current asthma management strategies,
demonstrating that they are effective in preventing the
worsening of symptoms in more than half of these
patients. However, future research should focus on the
unmet needs of the remaining patients who do not ben-
efit from their current asthma management.
Our study demonstrated that there were some dif-
ferences in HCRU between patients in the US and Eng-
land, despite the similar methodology used for analyzing
both datasets (including similar definitions to define
disease severity groups). This is to be expected as the two
populations were from different datasets coming from
different geographic settings and were exposed to differ-
ent health care systems, which could lead to different
clinical practices and different asthma management re-
gimens. First, the proportion of patients experiencing
exacerbations resulting in hospitalization or an ED visit
during the follow‐up period was generally higher in
England than in the US. Second, readmission within 90
days of a severe exacerbation was also higher in England
than in the US, as was the proportion of patients with ≥1
office visit, and this may be attributed to differences in
access and affordability of health care between these two
countries. Third, asthma‐specific office visits were higher
in the US than in England, and it is possible that general
practitioner visits in England may have covered issues in
addition to asthma, leading to an underestimation in the
number of asthma‐specific visits. Fourth, all‐cause and
asthma‐specific hospitalizations were higher in England
than in the US. Finally, there were also differences in the
proportions of patients on LABA monotherapy (almost
none in the US), and higher LTRA and OCS use were
seen in the US compared with England possibly due to
different concerns about safety, leading to different
country practices.
In this study, few patients had full blood eosinophil
count data available, making it difficult to clearly identify
those with eosinophilic asthma. It is possible that pediatri-
cians may consider it unhelpful to measure blood eosino-
phil counts in pediatric patients, unlike in adults in whom
blood testing is routinely performed. This is likely to explain
the low patient numbers in the severe refractory eosino-
philic asthma subgroup in our study. The number of
patients with blood eosinophil tests recorded was higher in
the US (6.7%) than in England (0.9%), perhaps owing to
differences in data sources or physician practices between
the two countries. Indeed, if we are to better understand
severe refractory asthma and severe refractory eosinophilic
asthma in the future, we need to identify those with ele-
vated eosinophils across countries.24,25
There are several limitations that should be taken into
account when considering the results from this analysis.
First, medication usage to assess GINA severity was de-
termined from the prescription information in the data-
bases rather than clinical assessment. Second, the
frequency of OCS‐defined exacerbations may have been
underestimated, as some patients had a supply of OCS at
home (particularly those who experienced frequent
exacerbations) and because the 20mg/d (prednisone
equivalent) cut‐off used in the US study to categorize
OCS‐defined exacerbations may have excluded younger
pediatric patients prescribed OCS at a lower dose. Third,
the lack of available patient‐reported outcome data or
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lung function measurements was also an issue. Finally,
findings from this study may not be generalizable to
other countries where practices differ and patients with
asthma may have different disease causations, history,
and progression that will impact their treatment regimen.
In conclusion, our results indicate that in pediatric
patients with asthma studied, the burden of asthma
tended to be higher as disease severity increased. In ad-
dition, our data provide an insight into the effectiveness
of current asthma management practices in the US and
England and point to subsets of patients with severe
disease who may have an unmet need for effective
treatment to minimize the risk of exacerbations and op-
timize clinical outcomes.
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